- Home
- TPST vs KNRX Comparison
TPST vs KNRX Comparison
Compare TPST & KNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TPST | KNRX |
|---|---|---|
| Founded | 2011 | 2009 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6M | 14.1M |
| IPO Year | 2012 | 2023 |
Fundamental Metrics
Financial Performance| Metric | TPST | KNRX |
|---|---|---|
| Price | $1.10 | $0.43 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $11.00 | N/A |
| AVG Volume (30 Days) | 241.2K | ★ 4.7M |
| Earning Date | 05-08-2026 | 06-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $295,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.84 | $0.31 |
| 52 Week High | $12.22 | $3.45 |
Technical Indicators
Market Signals| Indicator | TPST | KNRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.27 | 52.46 |
| Support Level | $1.02 | $0.39 |
| Resistance Level | $1.26 | $0.49 |
| Average True Range (ATR) | 0.10 | 0.04 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 59.98 | 38.47 |
Price Performance
Historical ComparisonAbout TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
About KNRX KNOREX LTD. Class A Ordinary Shares
Knorex Ltd is a B2B technology company providing programmatic advertising products and solutions to marketers to streamline and automate their advertising and marketing workflows. The company's product, Knorex XPOSM, is a self-service enterprise-grade cloud platform with a suite of advertising management and execution (AMX) applications.